SurModics to Webcast Fiscal 2008 Third Quarter Earnings Conference Call July 23

July 16, 2008 at 4:00 PM EDT

Webcast is Live at 4:00 p.m. (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--July 16, 2008--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its fiscal 2008 third quarter conference call on Wednesday, July 23, at 4:00 p.m. CT. The company will issue an earnings news release after the market closes that afternoon.

Bruce Barclay, president and chief executive officer, and Phil Ankeny, senior vice president and chief financial officer, will recap the third quarter financial results and accomplishments. To access the webcast, go to the investor relations portion of the company's website at the day of the conference call and click on the webcast icon. If you do not have access to the Internet and want to listen to the audio by phone, dial 800-240-8926.

An audio replay will be available beginning at 7:00 p.m. CT on Wednesday, July 23, until 7:00 p.m. CT on Wednesday, July 30 and can be accessed by dialing 800-405-2236 and entering conference call ID passcode 11116707. In addition, the conference call audio will be archived on the company's website following the call.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the healthcare industry. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in better patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the company, visit The content of SurModics' website is not part of this release or part of any filings the company makes with the SEC.

    CONTACT: SurModics, Inc.
             Phil Ankeny
             Senior Vice President and Chief Financial Officer
             (952) 829-2700

    SOURCE: SurModics, Inc.